3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Head & Neck
1
Gynecologic
1
Genitourinary
1
Gastrointestinal
1
Breast
1
Conditions
Endometrial Neoplasms
19
Ovarian Neoplasms
8
Uterine Cervical Neoplasms
7
Triple Negative Breast Neoplasms
4
Parkinson Disease 4, Autosomal Dominant Lewy Body
4
Neoplasms
4
Stomach Neoplasms
3
Squamous Cell Carcinoma of Head and Neck
3
Colorectal Neoplasms
3
Carcinoma, Transitional Cell
3
Carcinoma, Renal Cell
3
Carcinoma, Ovarian Epithelial
3
Carcinoma, Non-Small-Cell Lung
3
Carcinoma, Hepatocellular
3
Vulvar Neoplasms
2
Thyroid Neoplasms
2
Neoplasm Metastasis
2
Fallopian Tube Neoplasms
2
Advanced Endometrial Cancer
2
Adenocarcinoma
2
Urogenital Neoplasms
1
Urinary Bladder Neoplasms
1
Small Cell Lung Carcinoma
1
Recurrence
1
Pancreatic Neoplasms
1
Ovarian Diseases
1
Ovarian Clear Cell Carcinoma
1
Neoplasms, Glandular and Epithelial
1
Melanoma
1
Liver Neoplasms
1
Interventions
pembrolizumab
17
Carboplatin
10
Paclitaxel
7
Trastuzumab
5
Nivolumab
5
Gemcitabine
5
Early Intervention, Educational
5
Cyclophosphamide
5
Cisplatin
5
fludarabine
4
cemiplimab
4
Psychiatric Rehabilitation
4
Fluorouracil
4
Docetaxel
4
Counseling
4
Albumin-Bound Paclitaxel
4
tisotumab vedotin
3
belinostat
3
Radiotherapy
3
Polymerase Chain Reaction
3
Methods
3
Magnetic Resonance Spectroscopy
3
Gene Expression Profiling
3
Fluorodeoxyglucose F18
3
Biopsy
3
zimberelimab
2
ulixertinib
2
pertuzumab
2
palbociclib
2
osimertinib
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Urinary Bladder Neoplasms
×
lenvatinib
×
Gynecologic
×
Clear all
NCT05007106
2025-08-14
KEYVIBE-005
Merck Sharp & Dohme LLC
Phase 2
Completed
613 enrolled